or Try an Advanced Search...

    Transplant Rejection Stocks List

    Symbol Grade Name % Change
    ALKS F Alkermes plc 0.79
    CDNA F CareDx, Inc. 0.73
    BMY F Bristol-Myers Squibb Company -0.31
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major
    Related Stock Lists: Biopharmaceutical Depressive Disorder Diabetes Hypertension Organic Chemistry Schizophrenia Alcohol Angina Atrial Fibrillation Atypical Antipsychotics Biopharmaceutical Products Blood Test Cachexia Cancer Treatment Chemotherapy Cholesterol Chronic Myeloid Leukemia Clinic Clinical Medicine Cocaine

    Related ETFs - A few ETFs which own one or more of the above listed Transplant Rejection stocks.

    Symbol Grade Name Weight
    FTXH C First Trust Nasdaq Pharmaceuticals ETF 8.2
    MEDX F Horizon Kinetics Medical ETF 5.43
    IHE C iShares U.S. Pharmaceutical ETF 4.4
    XPH D SPDR S&P Pharmaceuticals ETF 4.3
    PPH C Market Vectors Pharmaceutical ETF 4.29
    View all Transplant Rejection ETFs...
    Compare ETFs
    Compare IHE to XPH Compare MEDX to IHE Compare XPH to PPH

        Transplant Rejection Stocks Recent News

        Date Stock Title
        Apr 23 BMY S&P 500 stocks with biggest estimated EPS declines for Q1
        Apr 23 BMY NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
        Apr 23 BMY Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook
        Apr 23 BMY Former Bristol Myers CEO tapped as Novartis’ next board chair
        Apr 22 ALKS Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
        Apr 22 BMY Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
        Apr 22 BMY Bristol-Myers, Cellares ink $380M CAR-T therapies supply deal
        Apr 22 BMY Is Bristol Myers Squibb A Buy At These Bottom Levels?
        Apr 22 BMY Curious about Bristol Myers (BMY) Q1 Performance? Explore Wall Street Estimates for Key Metrics
        Apr 22 BMY Bristol Myers taps startup to boost cell therapy production
        Apr 22 BMY Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
        Apr 21 BMY Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
        Apr 21 BMY Is Bristol-Myers Squibb (NYSE:BMY) Using Too Much Debt?
        Apr 20 BMY 3 High-Yielding Dividend Stocks That Are Trading at Dirt-Cheap Valuations
        Apr 19 CDNA CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
        Apr 19 BMY Got $500? 3 Healthcare Stocks to Buy and Hold Forever
        Apr 19 BMY FDA requires labeling changes to CAR-T cell therapies to reflect cancer risk
        Apr 18 BMY Earnings Preview: Bristol Myers Squibb (BMY) Q1 Earnings Expected to Decline
        Apr 18 CDNA CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last?
        Apr 17 ALKS Alkermes to Report First Quarter Financial Results on May 1, 2024
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major
        Related Stock Lists: Biopharmaceutical Depressive Disorder Diabetes Hypertension Organic Chemistry Schizophrenia Alcohol Angina Atrial Fibrillation Atypical Antipsychotics Biopharmaceutical Products Blood Test Cachexia Cancer Treatment Chemotherapy Cholesterol Chronic Myeloid Leukemia Clinic Clinical Medicine Cocaine
        Transplant Rejection

        Transplant rejection occurs when transplanted tissue is rejected by the recipient's immune system, which destroys the transplanted tissue. Transplant rejection can be lessened by determining the molecular similitude between donor and recipient and by use of immunosuppressant drugs after transplant.

        More about Transplant Rejection
        Browse All Tags